Where is the Novavax vaccine made and how effective is the jab the UK has ordered?
Get the latest Yorkshire breaking news and updates delivered straight to your inbox - sign up for free email updates Invalid Email Something went wrong, please try again later. Subscribe Thank you for subscribing We have more newsletters Show me See our privacy notice  As the end of lockdown is delayed until July, many in the UK are keeping a close eye on the vaccination rollout. The 23 and above age group is now able to book their first jab, meaning that most adults in the UK will soon be at least partially immunised. Pharmaceutical companies around the world are now vying to produce a vaccine that tackles the most infectious variants. Novavax is a vaccine company based in the US. Founded in the 80s, the company has recently focussed on creating a new Covid jab, but it's also worked on preventing diseases like Ebola and the flu. Alongside AstraZeneca, Moderna and Pfizer, the vaccinations created by the company will hopefully help in the worldwide effort to immunise the population. The companys coronavirus vaccine is officially called NVX-CoV2373. So far, the Novavax vaccine has been extremely effective in trial settings. In a study of nearly 30,000 people in the US and Mexico, NVX-CoV2373 has been 100% effective against moderate to severe diseases. More importantly, it was 93% effective against the alpha, beta and gamma variants (UK, South Africa, Brazil). While the Delta variant (first detected in India) wasnt in circulation at the time of the trial, the manufacturers said that it has a 91% efficacy in high-risk populations. Sign up to our free newsletters to receive our top stories to your inbox. We've got dedicated ones for Leeds, Sheffield, Harrogate, Doncaster, Wakefield, Harrogate, Halifax and the Yorkshire Coast too. It takes just seconds to sign up just click here, enter your email address and follow the instructions. Don't worry if you change your mind. You can 'unsubscribe' using the link at the bottom of every newsletter we send out. The UK has ordered 60 million doses of the Novavax vaccine, and the manufacturers will provide 1.1 billion doses to the UN-led Covax initiative. As booster jab trials continue in the UK, its thought that the new vaccine supply could be used for top-up doses in winter. In total, 41 million people in the UK have had their first jab, with nearly 30 million also having their second.